Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Equity Bottom-Up

This Insight summarizes the takeaways from a recent China healthcare industry conference focused on biopharmaceuticals and medical devices, and builds on our Originals Insight <a href="https://www.smartkarma.com/insights/asian-healthcare-coming-of-age" target="_blank" data-smartkarma-citation="insights:45676" rel="noopener">Asian Healthcare - Coming of Age</a>.  Topics addressed include value-based purchasing for drugs and devices; development of commercial health insurance; internet hospitals and online pharmacies; DRGs for hospitals; issues for medical device companies; and amendments to China's patent laws.

This Insight summarizes the takeaways from a recent China healthcare industry conference focused on biopharmaceuticals and medical devices, and builds on our Originals Insight Asian Healthcare - Coming of Age.  Topics addressed include value-based purchasing for drugs and devices; development of commercial health insurance; internet hospitals and online pharmacies; DRGs for hospitals; issues for medical device companies; and amendments to China's patent laws.

Equity Capital Markets

Eddingpharm is a China-based pharmaceutical company that has filed an Application Proof to list on the HKEX. The product line consist of older drugs with varying degrees of exposure to the government's VBP/GQCE program. The development pipeline has two intriguing candidates that should come to market in 2022. We think the overarching issue for the shares will be whether enthusiasm for the pipeline can offset the VBP-related overhang. 
This Insight addresses the company's products and market opportunity, and leave other topics to a future Insight. Our Bullish tag is a placeholder until we get closer to an offering.

Eddingpharm is a China-based pharmaceutical company that has filed an Application Proof to list on the HKEX. The product line consist of older drugs with varying degrees of exposure to the government's VBP/GQCE program. The development pipeline has two intriguing candidates that should come to market in 2022. We think the overarching issue for the shares will be whether enthusiasm for the pipeline can offset the VBP-related overhang. 
This Insight addresses the company's products and market opportunity, and leave other topics to a future Insight. Our Bullish tag is a placeholder until we get closer to an offering.

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

<a href="https://www.smartkarma.com/entities/edding-group-company-limited" target="_blank" data-smartkarma-citation="entities:29731:1" rel="noopener">Edding Group (EDG HK)</a> has filed its prospectus with the Hong Kong Stock Exchange for listing recently. The Company has established a highly differentiated and diversified product portfolio, mainly divided into three categories: anti-infectives, cardiovascular system and respiratory system. The following analyzed both the market potential and concerns for Edding.

Edding Group (EDG HK) has filed its prospectus with the Hong Kong Stock Exchange for listing recently. The Company has established a highly differentiated and diversified product portfolio, mainly divided into three categories: anti-infectives, cardiovascular system and respiratory system. The following analyzed both the market potential and concerns for Edding.

Pre-IPO Edding Group - Strong Core Products but Still Have Concerns

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Edding Group, a leading integrated pharmaceutical company in China, plans to raise up to USD 200m via a Hong Kong listing.The company is turning from a distributor of NMC drugs to a pharmaceutical company by acquiring product rights in the past two years. We are of the view that the Vancocin and Ceclor are the selling point of the company as they both have a dominant position in the respective segment and are in growing markets. The company's Vascepa is an interesting CVD product but the competition is intense given that the statin is the main therapy to reduce CV risks and it has many varieties with a competitive market. However, we do not see Mulpleta and EPD 125 attractive. Sales of Mulpleta are very small in Japan and the EDP125 was suspended by Eli Lilly previously given that it failed to demonstrate superiority in Phase II/III clinical trials. We think the management does not possess impressive working experience, though investor backing is strong.

Edding Group, a leading integrated pharmaceutical company in China, plans to raise up to USD 200m via a Hong Kong listing.The company is turning from a distributor of NMC drugs to a pharmaceutical company by acquiring product rights in the past two years. We are of the view that the Vancocin and Ceclor are the selling point of the company as they both have a dominant position in the respective segment and are in growing markets. The company's Vascepa is an interesting CVD product but the competition is intense given that the statin is the main therapy to reduce CV risks and it has many varieties with a competitive market. However, we do not see Mulpleta and EPD 125 attractive. Sales of Mulpleta are very small in Japan and the EDP125 was suspended by Eli Lilly previously given that it failed to demonstrate superiority in Phase II/III clinical trials. We think the management does not possess impressive working experience, though investor backing is strong.

Edding Group (亿腾医药) Pre-IPO: Distributor Turning Pharmaceutical

China

Pharmaceutical company focusing on three core therapeutic areas, namely anti-infectives, cardiovascular ('CV') and respiratory, by leveraging our market-tested full value chain capabilities.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Edding Group (EDG HK)

China Healthcare: Macro Themes

This Insight summarizes the takeaways from a recent China healthcare industry conference. There is much talk of pressures on the industry, but...

Kemp Dolliver, CFA

Eddingpharm: First Impressions

Eddingpharm plans to list on the HKEX. This Insight analyzes the company's products and pipeline. The main question is whether enthusiasm for the...

Kemp Dolliver, CFA

Pre-IPO Edding Group - Strong Core Products but Still Have Concerns

The article analyzed the market potential of its core products in three categories: anti-infectives, cardiovascular system and respiratory system,...

Xinyao (Criss) Wang

Edding Group (亿腾医药) Pre-IPO: Distributor Turning Pharmaceutical

The company is turning from a distributor of NMC drugs to a pharmaceutical company by acquiring product rights in the past two years.

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)